DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND AMONG CELL THERAPEUTICS, INC., BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA DATED: NOVEMBER 14, 2013Development, Commercialization and License Agreement • March 4th, 2014 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
This DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is entered into on this 14th day of November, 2013 (the “Effective Date”), by and among CELL THERAPEUTICS, INC., a company organized under the laws of the State of Washington with its principal place of business at 3101 Western Avenue, Seattle, WA 98121 (“CTI”), and BAXTER INTERNATIONAL INC., a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015 (“BII”), BAXTER HEALTHCARE CORPORATION, a company organized under the laws of Delaware with its principal place of business at One Baxter Parkway, Deerfield, IL 60015 (“BHC”), and BAXTER HEALTHCARE SA, a company organized under the laws of Switzerland with its principal place of business at Postfach 8010, Zurich, Switzerland (“BHSA” and together with BII and BHC, “Baxter”). CTI and Baxter may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Cell Therapeutics, Inc. Letterhead]Cell Therapeutics Inc • March 4th, 2014 • Pharmaceutical preparations
Reference is made to the performance-based stock award (the “Award”) granted to you by Cell Therapeutics, Inc. (the “Company”), effective as of [ ] and as subsequently amended, and evidenced by the Equity/Long-Term Incentive Award Agreement between you and the Company (the “Award Agreement”). This letter amendment (this “Amendment”) sets forth our agreement to amend the Award Agreement on the terms set forth herein. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Award Agreement.
